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Objective: A prospective randomized study was performed to test whether
removal of endothelin-1, by ultrafiltration techniques, will reduce pulmonary
hypertension after operations for congenital heart disease. Methods: Twenty-
four patients with pulmonary hypertension (systolic pulmonary/systemic arte-
rial pressure ratio > 60%) undergoing cardiac operations were randomized
into a control group (n 5 12) having conventional ultrafiltration and an
experimental group (n 5 12) undergoing dilutional ultrafiltration during and
modified ultrafiltration after cardiopulmonary bypass. Plasma endothelin-1,
nitric oxide metabolites, and cyclic guanosine monophosphate were assayed
before bypass, 10 minutes into bypass, after bypass, and 0, 3, 6, and 12 hours
after the operation in both groups, as well as in the ultrafiltrates and after
modified ultrafiltration in the experimental group. Both groups received
a-blockers (chlorpromazine and/or prazosin) postoperatively using the same
guidelines. Results: The ultrafiltrates contained significant amounts of endo-
thelin-1 (1.81 6 0.86 pg/ml, dilutional, and 6.44 6 1.82 pg/ml, modified
ultrafiltrate). Endothelin-1 and the pulmonary/systemic pressure ratio were
significantly lower in experimental compared with control patients. Nitric
oxide metabolites and cyclic guanosine monophosphate increased similarly in
both groups for 12 hours after the operation (p 5 not significant). Three of 12
control patients (25%) but no experimental patients had pulmonary hyperten-
sive crises (p 5 0.07). The experimental patients required significantly less
ventilatory support (67 6 47 hours vs 178 6 139 hours for control patients, p 5
0.048). Conclusions: Dilutional and modified ultrafiltration reduce endothelin-1
and the pulmonary/systemic pressure ratio postoperatively and may become an
important adjunct for preventing pulmonary hypertension after operations for
congenital heart disease in high-risk patients. (J Thorac Cardiovasc Surg 1998;
115:517-27)
Pulmonary hypertension associated with increasedpulmonary vascular resistance is a significant
cause of morbidity and mortality after the use of
cardiopulmonary bypass (CPB) for repair of con-
genital heart defects.1, 2 Although the precise mech-
anism of pulmonary hypertension after operation
for congenital heart disease remains poorly defined,
recent evidence suggests that pulmonary vascular
tone is regulated by a complex interaction of vaso-
active substances that are locally produced by the
vascular endothelium.3, 4
Endothelin-1 (ET-1) is a 21-amino acid polypep-
tide produced by vascular endothelial cells, the
potent vasoactive properties of which have been
implicated in the pathophysiology of pulmonary
hypertensive disorders.5 In patients with congenital
heart disease and pulmonary hypertension, plasma
concentrations of ET-1 increased immediately after
CPB and showed a significant correlation to the
ratio of pulmonary/systemic arterial pressure.6, 7 In
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addition, it has been shown in lambs with increased
pulmonary flow that pretreatment with ET-1 recep-
tor blockers eliminates the vasoconstrictive response
to alveolar hypoxia.8 These results suggest that
alterations in ET-1 induced during CPB may be
responsible in part for the increased pulmonary
vascular resistance and increased vascular reactivity
noted in children immediately after cardiac opera-
tions.
Modified ultrafiltration is a technique that uses
ultrafiltration of the patient and hemofiltration of
the CPB circuit after separation from bypass to
reverse hemodilution occurring during cardiac op-
erations.9, 10 In children undergoing CPB for repair
of congenital heart defects, modified ultrafiltration
has been shown to reduce total body water, increase
mean arterial pressure, increase cardiac index, and
decrease pulmonary vascular resistance.11, 12 More-
over, recent studies have demonstrated that some
low molecular weight inflammatory mediators can
be removed by hemofiltration during CPB.13, 14
Because the molecular weight of ET-1 is small
(2.5 kD),15 we hypothesized that ET-1 could be
removed using ultrafiltration techniques.16 We con-
ducted this randomized clinical trial to test the
hypothesis that removal of plasma ET-1 by ultrafil-
tration techniques will reduce pulmonary hyperten-
sion after operations for congenital heart disease in
which CPB is used.
Patients and methods
Twenty-four children with congenital heart disease as-
sociated with preoperative pulmonary hypertension
caused by high pulmonary flow who were undergoing
operations with the use of CPB at Riley Hospital for
Children between September and December 1996 were
included in this study. The study protocol was approved by
the Institutional Review Board of the Indiana University
School of Medicine. Informed consent was obtained from
the parents of each child.
Patient groups. Using a random number table, 24
patients were assigned to one of two groups as follows:
control group (n 5 12) using conventional ultrafiltration
and experimental group (n 5 12) using dilutional ultrafil-
tration (DUF) during CPB and modified ultrafiltration
(MUF) after CPB (DUF/MUF group). The preoperative
diagnoses and patient characteristics for each group are
depicted in Tables I and II. No significant differences were
observed between the groups with respect to patient
diagnoses and demographics.
Preoperative evaluation. Preoperative evaluation was
performed by cardiac catheterization in all patients with
ventricular septal defects (VSD), complete atrioventricu-
lar canal (CAVC), and three patients with transposition
and ventricular septal defect (TGA 1 VSD), and by
echocardiography in patients with total anomalous pulmo-
nary venous connection (TAPVC) and one patient with
TGA 1 VSD. Preoperative pulmonary hypertension was
defined as a systolic pulmonary/systemic arterial pressure
ratio (Pp/Ps) . 60% by catheterization. The three pa-
tients not catheterized (TAPVC in two, TGA 1 VSD in
one) had systemic or supersystemic pulmonary arterial
pressure as estimated by echocardiography.
Operative management. Operative management was
standardized during the time frame of this study. Cannu-
lation was accomplished by use of the ascending aorta for
inflow and separate caval cannulas inserted through the
right atrial appendage, superior vena cava, or both. CPB
was instituted at a flow rate of 2.4 L z min-1 z m-2, and the
perfusate was cooled to 20° to 28° C in most cases. The
pump prime consisted of an electrolyte solution (Plasma-
Lyte-A, Baxter Healthcare Corp.) 400 to 900 ml, sodium
bicarbonate 20 to 30 mEq, albumin 25% (12.5 gm/250 ml
of prime, to a final concentration of 5%) and washed
packed red blood cells sufficient to maintain a hematocrit
value of 14% to 18%. Ascorbic acid, 1 gm/10 kg, methyl-
prednisolone sodium succinate (SoluMedrol) 30 mg/kg,
and cefuroxime sodium 12.5 mg/kg were added to the
prime at the initiation of bypass. For patients with
TAPVC requiring circulatory arrest, a single venous can-
nula was used and the repair was performed after the
perfusate was cooled to 15° C and maintained for 15
minutes. The left side of the heart was vented with a
catheter inserted through the apex of the left ventricle or
the left atrial appendage. Cold crystalloid cardioplegic
solution was injected at a total volume of 15 ml/kg.
Topical hypothermia was added. The infusion of car-
dioplegic solution was repeated at 20- to 25-minute inter-
vals or sooner if electrical activity was noted.
Technique of conventional ultrafiltration. In the con-
ventional ultrafiltration group, patients were treated with
ultrafiltration during CPB, which removed excess fluid
when it was present (n 5 8) and hemoconcentrated the
patient’s blood. The total amount of fluid filtered by
conventional ultrafiltration was 20.6 6 8.2 ml/kg. Post-
CPB processing of blood from the extracorporeal circuit
by a centrifugal red cell salvage process was also used in
these patients.
Techniques of dilutional ultrafiltration. The DUF/
MUF patients received an augmented form of ultrafiltra-
tion during CPB. In this dilutional ultrafiltration method,
the patient-CPB circuit is actively exchanged by (1) setting
the circuit parameters to allow ultrafiltrate formation at a
rate equivalent to the crystalloid cardioplegia volume plus
Table I. Preoperative diagnosis
Control DUF/MUF
VSD 1 PH 6 5
CAVC 3 4
TGA 1 VSD 2 2
TAPVC 1 1
Total 12 12
DUF, Dilutional ultrafiltration; MUF, modified ultrafiltration; VSD, ven-
tricular septel defect; PH, pulmonary hypotension; CAVC, complete
atrioventricular canal; TGA, transposition of great arteries; TAPVC, total
anomalous pulmonary venous connection.
The Journal of Thoracic and
Cardiovascular Surgery
March 1998
5 1 8 Bando et al.
40 to 70 ml/kg per hour and (2) adding small aliquots of
diluent (PlasmaLyte A , 20 ml/kg) as necessary to
maintain a safe blood level in the venous reservoir of the
CPB circuit. The dilutional ultrafiltration was carried out
semicontinuously throughout the CPB run but was inter-
rupted during weaning from CPB while inotropic or
vasoactive drugs were being administered.16
Techniques of modified ultrafiltration. A venovenous
modified ultrafiltration method was used on all patients in
the DUF/MUF group. In this method, the patient’s infe-
rior vena caval blood was drawn into the modified ultra-
filtration circuit (Fig. 1) through the tip of a dual-lumen
hemodialysis catheter. The inferior vena caval blood
within the modified ultrafiltration circuit was both ultra-
filtered with a hemoconcentrator (model HPH400,
Minntech, Minneapolis, Minn.) and oxygen-supple-
mented with aliquots of oxygenated, warmed CPB circuit
blood that had previously been translocated to a reservoir.
Aliquots of this oxygenated blood were administered
during modified ultrafiltration to maintain appropriate
filling pressures as ultrafiltrate was being formed. After
being oxygen-supplemented and ultrafiltered, the modi-
fied ultrafiltration circuit blood was returned to the pa-
tient’s right atrium through the proximal side holes of the
dual-lumen catheter. Modified ultrafiltration was termi-
nated when the supplement reservoir bag was empty. The
duration of modified ultrafiltration was not measured in
this study, but in prior pilot study, modified ultrafiltration
was completed in 12 6 3 minutes. The total amount of
fluid filtered by dilutional ultrafiltration and modified
ultrafiltration was 45.8 6 17.5 ml/kg, 124.7 6 25.6 ml/kg,
respectively.
After modified ultrafiltration, the dual-lumen cannula
was removed, protamine was administered, and the pa-
tients were transfused as required with the residual mod-
ified ultrafiltration circuit blood. Protamine reversal was
completed after the modified ultrafiltration circuit blood
transfusions.
Intraoperative postrepair evaluation and monitoring.
As patients were being warmed and weaned from bypass,
pulmonary arterial, left atrial, and right atrial oximetric
catheters were inserted for intraoperative and postopera-
tive hemodynamic monitoring. Intraoperative nitroglyc-
erin at a dose of 0.5 to 10 mg/kg per minute and
nitroprusside at a dose of 3 mg/kg per minute were given
in the early postoperative period. These agents were
administered through a right atrial or pulmonary arterial
line and titrated to keep Pp/Ps , 40%. If dopamine or
dobutamine was required at a dose of . 5 mg/kg per
minute, it was delivered through the left atrial line in an
attempt to reduce the potential for inducing pulmonary
vasoconstriction.
Prevention strategy for postoperative pulmonary hy-
pertension. Postoperative pulmonary hypertensive events
included pulmonary hypertensive crises and persistent
pulmonary hypertension. A pulmonary hypertensive crisis
was defined as a syndrome of hyperacute rise in the
systolic pulmonary/systemic pressure ratio (Pp/Ps . 70%)
accompanied by a profound reduction in cardiac output
and fall in Svo2. Persistent pulmonary hypertension was
defined as a postoperative Pp/Ps . 70% continuing for
longer than 6 hours after repair. Patients in both groups
were paralyzed and mechanically ventilated for at least 6
hours. Moderate hyperventilation was used when the
Pp/Ps ratio exceeded 40%.
Both groups received prophylactic a-blockers (chlor-
promazine and/or prazosin) after CPB on the basis of a
routine clinical protocol. Intravenous administration of
chlorpromazine was begun in the immediate postopera-
tive period at a dose of 0.25 mg with adjustments for its
pulmonary vasodilatory (a-adrenergic blockade) and cen-
tral nervous system sedative effects as needed to a maxi-
mum of 2 mg every 4 hours. If pulmonary hypertension
(Pp/Ps . 50 %) persisted after administration of chlor-
promazine, prazosin (another a-blocker) was given orally
or by nasogastric tube beginning with 0.125 mg and
titrating up to 2 mg every 4 hours.
Strategy for extubation. The protocol for initial respi-
ratory management consisted of mechanical ventilator
support to maintain Pao2 . 120 mm Hg, Paco2 > 30 to 35
mm Hg, and pH > 7.45 to 7.50 to achieve minimal
physiologic response to stimulation. Once the child exhib-
ited hemodynamic stability for 12 to 24 hours, mechanical
ventilatory support and sedation were weaned. When the
child demonstrated the ability to sustain adequate spon-
taneous respiratory effort and required minimal supple-
mental oxygen as reflected by normal arterial blood gases,
the child was extubated.
Measurement of ET-1, nitric oxide metabolites, and
cyclic guanosine monophosphate. A 4 ml blood sample
was collected from the radial artery in a Vacutainer device
(Becton Dickinson Vacutainer Systems, Franklin Lakes,
N.J.) containing 500 KU aprotinin to measure plasma
ET-1, nitric oxide (NO) metabolites, and cyclic guanosine
monophosphate (cGMP) at seven time points: immedi-
ately before CPB, 10 minutes into CPB, immediately after
CPB, and 0, 3, 6, and 12 hours after CPB. The plasma was
separated immediately by centrifugation and stored at
–70° C until ET-1, NO, and cGMP were assayed.
The ET-1 assay was based on a two-site immunoenzy-
mometric “sandwich” method (Amersham Life Science,
Arlington, Ill.). ET-1 extracted by solid phase column
chromatography from plasma samples was incubated with
an IgG anti-endothelin antibody overnight at 4° C. ET-1
bound to anti-endothelin antibody was detected using a
horseradish peroxidase conjugated anti-ET-1 F ab9 frag-
ment and compared with standard samples of known
amounts of synthetic ET-1. The color developed after the
addition of substrate was measured at 450 nm. A standard
Table II. Patient demographics
Control DUF/MUF p Value
Gender (M/F) 6/6 6/6
Age (days) 223 6 151 180 6 167 0.33
Weight (kg) 7.4 6 4.8 5.2 6 1.3 0.16
Preop Qp/Qs 2.8 6 0.4 3.1 6 0.5 0.57
CPB time (min) 130 6 36 143 6 50 0.49
Ao clamp time
(min)
73 6 19 78 6 35 0.73
DUF, Dilutional ultrafiltration; MUF, modified ultrafiltration; Qp/Qs, ratio
of pulmonary versus systemic flow; CPB, cardiopulmonary bypass; Ao,
aortic.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 115, Number 3
Bando et al. 5 1 9
curve was constructed and the amount of ET-1 present in
the plasma was expressed as picograms per milliliter.
NO was measured using a commercially available kit
(Boehringer Mannheim, Indianapolis, Ind.). Nitrate
present in the sample was reduced to nitrite by reduced
nicotinamide adenine dinucleotide phosphate and nitrate
reductase. The red-violet diazo dye formed by the addi-
tion of sulfanilamide and N-1-naphthlyl-ethylenediamine
dihydrochloride was measured at 550 nm, and the con-
centration of NO metabolites was calculated from a
calibration curve ranging from 0.8 mmol/L to 80 mmol/L.
NO values were expressed as micromoles per liter of NO
metabolites.
The cGMP assay (Amersham Life Science, Arlington,
Ill.) was based on competition between unlabeled cGMP
and a fixed quantity of peroxidase-labeled cGMP in the
presence of a limited amount of cGMP-specific antibody.
The concentration of cGMP in the sample was deter-
mined by interpolation of a standard curve (0 to 512
pg/well) and expressed as picograms per milliliter.
Because we intentionally diluted blood during CPB in
the DUF/MUF group, the effect of hemodilution during
CPB was not corrected for in this study.
Postoperative evaluation. A complete set of postoper-
ative physiologic data was collected for all 24 patients,
including arterial blood gas (oxygen tension, carbon diox-
ide tension, and pH), requirement for inotropic support,
cardiac rhythm, right atrial pressure, pulmonary arterial
pressure, and systemic pressure. Postoperative hematocrit
levels and requirements for red blood cells, platelets, and
fresh frozen plasma were also collected. The duration of
intubation and chest tube drainage were also monitored.
Statistical analysis. Data were analyzed with both the
SAS (Statistical Analysis System, Inc., Cary, N.C.) and
Fig. 1. Venovenous modified ultrafiltration circuit. In preparation for modified ultrafiltration, blood
within the cardiopulmonary bypass circuit from the venous line through to the arterial filter was first
crystalloid-chased to the modified ultrafiltration supplement bag reservoir. Modified ultrafiltration is next
conducted during the post-cardiopulmonary bypass period by removing the tube clamps at circuit location
D, J, and K and adjustment of microscrew clamp I to obtain an ultrafilter pressure of 400 mm Hg while
modified ultrafiltration pump flow rate is 10 to 30 ml/kg per minute. As ultrafiltered waste fluid is formed,
the patient’s central venous pressure is maintained by intermittently adding modified ultrafiltration
supplement to blood by briefly moving the tubing clamp at location E to site D. Dilutional ultrafiltration
is performed during cardiopulmonary bypass by placing the ultrafiltered blood recirculator line at stopcock
position 2. Dotted lines indicate the modified ultrafiltration circuit. Letters within circles (A through K)
define potential positions(s) of tubing clamps for various uses of the circuit. Numbers within circles define
alternate stopcock attachment points of the ultrafiltered blood recirculation line. CPS, Cardioplegic
solution; IVC, inferior vena cava; MUF, modified ultrafiltration; UF, ultrafiltered.
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STATISTICA (Statsoft, Tulsa, Okla.) software pack-
ages. Differences in the levels of plasma ET-1, NO
metabolites, cGMP, and the Pp/Ps ratios between the
groups were determined by ANOVA for repeated
measures. The changes in ET-1, NO metabolites,
cGMP, Pp/Ps within each group were compared be-
tween, before, and 12 hours after the operation by
paired t test. The incidence of postoperative pulmonary
hypertensive crises and the requirement for a-blocker
prophylaxis and inotropic support were compared be-
tween the groups by Fisher’s exact test. The duration of
ventilatory support was compared between the groups
using an unpaired t test. All values were expressed as
mean 6 standard deviation.
Results
Perioperative management, mortality, and inci-
dence of postoperative pulmonary hypertension.
No significant differences between the groups in
CPB time or aortic crossclamp time were observed.
The requirements for NO donors and inotropic
support for each group were also similar between
the groups. As evident in Appendix 1, the require-
ment for prazosin was similar between the groups.
However, high doses of chlorpromazine (.1.5 mg)
were required in 25% (3/12) of patients in the
control group but not in the DUF/MUF group. No
mortality occurred among the patients in this study.
Three of 12 patients in the control group (25%) but
none of DUF/MUF patients experienced postoper-
ative pulmonary hypertensive crises (p 5 0.22).
None of the patients in this study had persistent
pulmonary hypertension after operation.
Perioperative changes of ET-1. The dynamic
changes of ET-1 levels before and during CPB, at
the end of modified ultrafiltration (DUF/MUF
group only), and up to 12 hours after operation
are depicted in Fig. 2. Plasma ET-1 increased
slightly during CPB in both groups. In the DUF/
MUF group, 6.44 6 1.82 pg/ml of ET-1 was
removed during modified ultrafiltration after
CPB, whereas only 1.81 6 0.86 pg/ml of ET-1 was
removed in the dilutional ultrafiltration filtrate
during CPB. Subsequently, plasma ET-1 levels
were significantly lower after modified ultrafiltra-
tion and remained low up to 12 hours after
operation. In sharp contrast, ET-1 levels in the
control group were substantially increased after
CPB and remained significantly higher than in the
DUF/MUF group throughout the study period.
Perioperative changes of Pp/Ps. Preoperative
Pp/Ps were similar between the groups. However, at
the end of the operations, Pp/Ps in the control group
were significantly higher compared with the DUF/
MUF group, and this was maintained for up to 12
hours after operation (Fig. 3).
Perioperative changes in NO metabolites (NO2/
NO3) and cGMP. NO production, as measured by
the metabolites NO2/NO3, increased significantly in
both groups during and after operation, and this
persisted beyond 6 hours (Fig. 4, A). The changes in
cGMP were similar in both groups (Fig. 4, B). No
significant differences were observed between the
groups with respect to either NO2/NO3 or cGMP
throughout the study period.
Perioperative arterial blood gases and ventilator
requirement after operation. Immediately after op-
eration, oxygen tension (Po2) in the DUF/MUF
group (430.0 6 91.0 mm Hg) was significantly higher
than that of the control group (282.0 6 66.5 mm Hg)
(p , 0.05). The pH was maintained . 7.4 in all
patients after operation, and no significant differ-
ences in this parameter were observed between the
groups during the first 12 hours after operation
(Appendix 3). Patients treated with DUF/MUF
required significantly shorter durations of ventila-
tory support (68 6 47 hours) compared with control
patients (178 6 139 hours) (p 5 0.048).
Requirement for blood transfusion. The require-
ment for platelets and fresh frozen plasma through
postoperative day 1 were significantly higher in
control patients compared with DUF/MUF patients
(Appendix 4).
Discussion
The mediators involved in the pulmonary hyper-
tension after CPB in patients with congenital heart
Fig. 2. Changes of arterial plasma endothelin-1 concen-
tration at different times during perioperative period.
ET-1, Endothelin-1; DUF, dilutional ultrafiltration; MUF,
modified ultrafiltration. †p , 0.01 versus control group.
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disease have been the focus of clinical and basic
research for several years, and considerable progress
has been made in identifying the mechanisms un-
derlying this response. Pulmonary vascular tone is
modulated by the vascular endothelium, which
maintains a balance between vasodilators and vaso-
constrictors. CPB alters the balance by impairing
endothelium-dependent vasodilatation17, 18 and in-
creasing production of vasoconstrictors.19, 20 Recent
studies have shown that in patients with preopera-
tive pulmonary hypertension, plasma ET-1 levels
increase after CPB, resulting in significant postop-
erative pulmonary hypertension.7, 21
Because ET-1 increases significantly during and
immediately after CPB, we tested whether the use of
aggressive hemofiltration during and after CPB can
successfully remove ET-1 and reduce pulmonary
hypertension in high-risk patients with congenital
heart disease.
This study demonstrates that combined dilutional
and modified ultrafiltration efficiently removes free
water (170.0 6 43.1 ml/kg) compared with conven-
tional ultrafiltration (20.6 6 8.2 ml/kg). Conse-
quently, this efficient ultrafiltration technique re-
moved a significant amount of the circulating ET-1
(1.81 6 0.86 pg/ml in the DUF ultrafiltrate, 6.44 6
1.82 pg/ml in the MUF filtrate) and maintained
significantly lower plasma ET-1 levels compared
with the control group. Subsequently, the Pp/Ps
ratio in the DUF/MUF group was significantly lower
compared with the control group for 12 hours after
operation. As a result, 3 of 12 control patients
(25%), but none of the DUF/MUF patients had
pulmonary hypertensive crises after CPB. More-
over, perhaps as a result of the reduced Pp/Ps ratio,
patients treated with DUF/MUF required signifi-
cantly less ventilatory support.
This study cannot imply that ET-1 is the only source
of postoperative pulmonary hypertension. Removal of
free water and lower transfusion requirements may
contribute to improved pulmonary mechanics after
CPB22 and result in significantly lower postoperative
Pp/Ps and earlier extubation in the DUF/MUF pa-
tients. Removal of other cytokines, including tumor
necrosis factor and interleukin-6 and 8, by ultrafiltra-
tion may also play a significant role in reducing post-
reperfusion lung injury.10, 23
This study also does not indicate that DUF/MUF
is a “magic bullet” for prevention of postoperative
pulmonary hypertension. In our pilot study, a
6-month-old baby with CAVC associated with Down
syndrome had a complete repair performed. Dilu-
tional and modified ultrafiltration were used during
and after CPB, and the Pp/Ps was 30% on arrival in
the intensive care unit. This child did not have
a-blocker prophylaxis, and 3 hours after intensive
care unit admission, he had a pulmonary hyperten-
sive crisis and required cardiopulmonary resuscita-
tion and extracorporeal membrane oxygenation sup-
port for 5 days. We speculated that this may have
been due to significant ET-1 production several
hours after the cessation of bypass and modified
ultrafiltration therapy. In addition, another vasocon-
strictor such as thromboxane B2 might have played a
significant role in the development of this pulmo-
nary hypertensive event. Fortunately, this baby was
successfully weaned from extracorporeal membrane
oxygenation and survived. However, we learned a
lesson from this experience that routine prophylaxis
of postoperative pulmonary hypertension using
a-blockers, moderate hyperventilation, and sedation
cannot be omitted.
The relative importance of dilutional ultrafiltra-
tion versus modified ultrafiltration remains unclear
after this study. During CPB, ET-1 levels increased
slightly in both groups and no significant differences
were observed between groups. This implies that
significant ET-1 is being produced during CPB, and
dilutional ultrafiltration may not be effective enough
to remove the excess ET-1 because the total amount
of ET-1 in the dilutional ultrafiltration filtrate
(1.81 6 0.86 pg/ml) was significantly lower com-
pared with that in the modified ultrafiltration filtrate
Fig. 3. Changes of Pp/Ps at different times during the
perioperative period. Pp/Ps, Systolic pulmonary/systemic
arterial pressure ratio; DUF, dilutional ultrafiltration;
MUF, modified ultrafiltration. *p , 0.05 versus control
group; †p , 0.01 versus control group.
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(6.40 6 1.82 pg/ml). Recently, Journois and col-
leagues24 studied the effect of combined use of
arteriovenous modified ultrafiltration (after CPB)
with a high-volume, zero-balance hemofiltration
(during CPB) and found improved outcomes in the
combined group compared with modified ultrafiltra-
tion alone. In their study, zero-balance ultrafiltra-
tion was performed only during the rewarming
phase of CPB, whereas dilutional ultrafiltration was
performed throughout CPB in our study. Moreover,
the total amount of zero-balance ultrafiltrate was
approximately three times the volume filtered by
modified ultrafiltration in their study, whereas only
one third of the amount of fluid filtered during
modified ultrafiltration was removed by dilutional
ultrafiltration in our study. Because the filtration
techniques during CPB were widely different be-
tween these two studies, it is difficult to compare
these findings. Nonetheless, we plan to perform a
comparison of groups treated with dilutional ultra-
filtration during CPB alone versus modified ultrafil-
tration after CPB. This future study might help
determine whether dilutional ultrafiltration is nec-
essary for effective removal of vasoactive mediators.
This prospective clinical study has several limita-
tions. Radial artery samples were used to assess
ET-1, NO metabolites, and cGMP. Thus the
transpulmonary gradient of these mediators could
not be assessed. However, in a sample of four
patients, the concentration of ET-1 drawn simulta-
neously from the right and left atria and the pulmo-
nary artery were similar in both control (n 5 2) and
the DUF/MUF patients (data not shown). This
study and others demonstrated that plasma levels of
ET-1 are elevated after CPB, and the ET-1 levels
correlate well with the degree of pulmonary hyper-
tension.6, 8, 21 However, because 90% of ET-1 is
secreted by the vascular endothelium toward the
vessel media, the significance of increased plasma
levels can only be inferred. The local concentration
of ET-1 may be more important than circulating
levels in determining the response of a vascular
bed.25 Further study, including measurement of
ET-1 messenger RNA and ET-1 receptor expression
in the pulmonary artery and lungs26 in animal
models or patients with pulmonary hypertension will
be necessary.7, 8
In addition, other vasoactive mediators, including
prostacyclin, thromboxane, and platelet-activating fac-
tor, were not measured because of the volume of
blood required. The impact of residual intracardiac
shunts, pulmonary stenosis, or both on postoperative
pulmonary flow and pressure must also be considered.
Two minimal residual shunts after CAVC repair and
one mild pulmonary stenosis after TGA 1 VSD repair
were detected by intraoperative echocardiography in
this series. These were not considered to be physiolog-
ically significant, but their impact on vasoactive medi-
ators could not be assessed.
Temperature and flow of CPB are important
factors in determining the production of ET-1 and
other cytokines after CPB and subsequent develop-
ment of pulmonary hypertension.11, 27 In this ran-
Fig. 4. A, Changes of plasma NO2/NO3 levels at different
times during perioperative period. Postoperative plasma
NO2/NO3 levels were significantly higher than preopera-
tive levels and no significant differences were observed
between two groups. B, Changes of plasma cyclic
guanosine monophosphate levels at different times during
perioperative period. Postoperative plasma NO2/NO3 lev-
els were significantly higher than preoperative levels and
no significant differences were observed between two
groups. cGMP, Cyclic guanosine monophosphate; DUF,
dilutional ultrafiltration; MUF, modified ultrafiltration.
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domized study, one patient with total anomalous
pulmonary venous return in each group underwent
repair with total circulatory arrest. The systemic
temperature and CPB flow rates in the other pa-
tients were similar between the groups. Nonetheless,
the impact of bypass temperature and flow on
postoperative ET-1 production and pulmonary hy-
pertension needs to be evaluated.
Another potentially confounding factor in this
study is the use of inotropic agents postoperatively.
This was not uniform for every patient, but con-
formed to general guidelines established by the
attending physicians. Although administration of
inotropic agents may have changed the balance of
pulmonary vascular tone in some patients, this could
not be independently analyzed because of the rela-
tively small number of patients in each group.
However, no differences were observed in the mean
use of dopamine and dobutamine between the
groups of patients (Appendix 1).
In conclusion, higher levels of ET-1 may predis-
pose patients to pulmonary hypertension after op-
erations for congenital heart defects. A combination
of dilutional and modified ultrafiltration reduced
plasma ET-1 and the pulmonary/systemic pressure
ratio after CPB and resulted in lower ventilator
requirements. Thus the use of aggressive ultrafiltra-
tion techniques during and after CPB may represent
an important adjunct for the prevention of pulmo-
nary hypertension early after operations for congen-
ital heart disease in high-risk patients.
R E F E R E N C E S
1. Hopkins RA, Bull C, Haworth SG, de Leval MR, Stark J.
Pulmonary hypertensive crises during cardiac surgery for
congenital heart defects in young children. Eur J Cardiotho-
rac Surg 1991;5:628-34.
2. Bando K, Turrentine MW, Sharp TG, Sekine Y, Aufuero
TX, Sun K, et al. Pulmonary hypertension after operations
for congenital heart disease: analysis of risk factors and
management. J Thorac Cardiovasc Surg 1996;112:1600-9.
3. Vane JR, Anggard EE, Botting RM. Regulatory functions of
the vascular endothelium. N Engl J Med 1990;323:27-36.
4. Cooper CJ, Landsberg MJ, Anderson TJ, Charbonneau F,
Creager MA, Ganz P, et al. Role of nitric oxide in the local
regulation of pulmonary vascular resistance in humans. Cir-
culation 1996;93:266-71.
5. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Koba-
yashi M, Mitsui Y, et al. A novel potent vasoconstrictor
peptide produced by vascular endothelial cells. Nature 1988;
332:411-5.
6. Komai H, Adatia IT, Elliot MJ, de Leval MR, Haworth SG.
Increased plasma levels of endothelin-1 after cardiopulmo-
nary bypass in patients with pulmonary hypertension and
congenital heart disease. J Thorac Cardiovasc Surg 1993;106:
473-8.
7. Bando K, Vijayaraghavan P, Turrentine MW, Sharp TG,
Morelock RJ, Brown JW. Dynamic changes of endothelin-1,
nitric oxide and cyclic GMP in patients with congenital heart
disease. Circulation 1997;96(Suppl):II346-51.
8. Reddy VM, Hendricks-Munoz KD, Rajasinghe HA, Petros-
sian E, Hanley FL, Fineman JR. Post-cardiopulmonary by-
pass pulmonary hypertension in lambs with increased pulmo-
nary blood flow: a role for endothelin-1. Circulation 1997;95:
1054-61.
9. Naik SK, Knight A, Elliott MJ. A successful modification of
ultrafiltration for cardiopulmonary bypass in children. Perfu-
sion 1991;6:41-50.
10. Elliott MJ. Ultrafiltration and modified ultrafiltration in pedi-
atric open heart operations. Ann Thorac Surg 1993;56:1518-22.
11. Naik SK, Knight A, Elliott M. A prospective randomized study
of a modified technique of ultrafiltration during pediatric open-
heart surgery. Circulation 1991;84(Suppl):III422-31.
12. Naik SK, Elliott MJ. Ultrafiltration and pediatric cardiopul-
monary bypass. Perfusion 1993;8:101-12.
13. Anderson S, Gothberg S, Berggren H, Bengtsoon A, Eriks-
son E, Risburg B. Hemofiltration modifies complement
activation after extracorporeal circulation in infants. Ann
Thorac Surg 1993;56:1515-7.
14. Millar AB, Armstrong L, van der Linden J, et al. Cytokine
production and hemofiltration in children undergoing cardio-
pulmonary bypass. Ann Thorac Surg 1993;56:1499-502.
15. Goto K, Hama H, Kasuya Y. Molecular pharmacology and
pathophysiological significance of endothelin. Jpn J Pharma-
col 1996;72:261-90.
16. LaLone BJ, Frederick CC, Horner MT, Richmond LH,
Bezruczko AP, Morris SM, et al. Modified ultrafiltration
after congenital heart surgery: a venovenous method using a
dual lumen hemodialysis catheter [abstract]. AmSECT Today
1997;3:29.
17. Wessel DL, Adatia I, Giglia TM, Thompson JE, Kulik TJ.
Use of inhaled nitric oxide and acetylcholine in the evalua-
tion of pulmonary hypertension and endothelial function
after cardiopulmonary bypass. Circulation 1993;88(pt 1):
2128-38.
18. Kirshbom PM, Jacobs MT, Tsui SS, et al. Effects of cardio-
pulmonary bypass and circulatory arrest on endothelium
dependent vasodilation in the lung. J Thorac Cardiovasc Surg
1996;111:1248-56.
19. Shafique T, Johnson RG, Dai HB, Weintraub RM, Johnson
RG. Cardiopulmonary bypass and pulmonary thromboxane
generation. Ann Thorac Surg 1993;55:724-8.
20. Cave AC, Manche A, Derias NW, Hearse DJ. Thromboxane A2
mediates pulmonary hypertension after cardiopulmonary by-
pass in the rabbit. J Thorac Cardiovasc Surg 1993;106:959-67.
21. Hiramatsu T, Imai Y, Takanashi Y, et al. Time course of
endothelin-1 and nitrate anion levels after cardiopulmonary
bypass in congenital heart defects. Ann Thorac Surg 1997;63:
648-52.
22. Meliones JN, Gaynor JW, Wilson BG, et al. Modified
ultrafiltration reduces airway pressures and improves lung
compliance after congenital heart surgery. J Am Coll Cardiol
1995;27:1A.
23. Journois D, Pouard P, Greeley WJ, Mauriat P, Vouhe P,
Safran D. Hemofiltration during cardiopulmonary bypass in
pediatric cardiac surgery: effects on hemostasis, cytokines,
and complement components. Anesthesiology 1994;81:
1181-9.
The Journal of Thoracic and
Cardiovascular Surgery
March 1998
5 2 4 Bando et al.
24. Journois D, Israel-Biet D, Pouard P, et al. High-volume,
zero-balanced hemofiltration to reduce delayed inflamma-
tory response to cardiopulmonary bypass in children. Anes-
thesiology 1996;86:965-76.
25. Rubanyi GM, Polokoff MA. Endothelins: molecular biology,
biochemistry, pharmacology, and pathophysiology. Pharma-
col Rev 1994;46:338-44.
26. Kirshbom PA, Page SO, Jacobs MT, et al. Cardiopulmonary
bypass and circulatory arrest increase endothelin-1 produc-
tion and receptor expression in the lung. J Thorac Cardiovasc
Surg 1997;113:777-83.
27. Skaryak LA, Kirshbom PM, DiBernardo LR, et al. Modified
ultrafiltration improves cerebral metabolic recovery after
circulatory arrest. J Thorac Cardiovasc Surg 1995;109:744-52.
Discussion
Dr. Ross M. Ungerleider (Durham, N.C.). When our
group first began using ultrafiltration several years ago,
there were very little data to justify its widespread use, and
the technique did not gain general acceptance for several
years. It has now been demonstrated from a variety of
laboratory and clinical studies, some by us and many by
others, that modified ultrafiltration acutely improves car-
diac and pulmonary function after bypass and quite
possibly cerebral recovery in patients exposed to periods
of deep hypothermic circulatory arrest. Furthermore, it
has been suggested that these improvements are related to
the proven ability of modified ultrafiltration to remove
excess water and low molecular weight mediators from the
patient. It is now becoming more commonplace to find
groups using ultrafiltration, at least in the neonatal and
infant population, and many groups who use variations of
the technique are impressed that it is indeed doing
something beneficial for their patients compared with
when ultrafiltration is not used.
In your study you compared conventional ultrafiltration
with a technique that combined filtration on bypass and
filtration after bypass. It is not clear how much actual
filtration was accomplished in your control group because
you state that filtration was performed only when fluid was
available. Therefore it seems that you are basically com-
paring a group with no effective filtration to a second
group exposed to two kinds of effective filtration. What
was the average amount of fluid filtered for the control
group? Did you measure the endothelin-1 in the filtrate
obtained by each separate method?
Some surgeons are reluctant to use post-bypass filtra-
tion for fear of creating patient instability. In a future
study, as you mentioned, could you compare your on-
bypass dilutional filtration, which at least appears to be a
somewhat effective and consistent modality for on-bypass
filtration in your hands, to postbypass modified ultrafiltra-
tion? Why did you design your study so that you combine
the impact of dilutional and modified ultrafiltration? It
might be that they will provide equivalent clinical advan-
tage, especially with respect to the parameters that you
followed in these patients. Because of your study design,
you really have not answered whether post-bypass filtra-
tion is superior to effective on-bypass filtration, at least
with respect to postoperative pulmonary hypertension and
circulating endothelin-1 levels.
The other aspect of your study that is worthy of
comment is the nature of endothelin-1, which acts on
vascular smooth muscle. You address this in your discus-
sion, but it is important to emphasize. Because circulating
endothelin-1 probably does not affect vascular smooth
muscle, how can we know that what you are measuring
reflects a comparable increase or decrease in endothelin-1
effect on the pulmonary vascular smooth muscle? Your
graph, for example, displays pulmonary/systemic pressure
ratios. What are the actual pulmonary artery pressures
and systemic pressures? Could your difference reflect the
improvement in systemic artery pressure, which is well
known after modified ultrafiltration because this will
lower the pulmonary/systemic ratios irrespective of the
endothelin-1 levels? Your conclusions are convincing, but
please comment on how cautious we should be in inter-
preting these data.
Finally, it is important to realize that as effective as
ultrafiltration appears to be in your patients, it is being
applied after the injury has occurred. It seems to be
effective at reducing the clinical impact of bypass-induced
injury, but could you speculate for a moment about the
injury itself? Could you recognize any factors that seem to
relate to a greater likelihood of post-bypass pulmonary
hypertension? Although your group seems to be well
controlled, the preoperative Po2 in the control group is
lower. Our laboratory has found that preoperative hyp-
oxia may relate to lung injury. Did all groups have
so-called total bypass? We found, and will be presenting
elsewhere, information that suggests that a lack of flow to
the pulmonary arteries during bypass increases post-
bypass lung injury. Observations by astute clinicians can
be helpful. Do you have any sense despite the clinical
sameness of your groups for factors that might make
patients most susceptible to bypass-related pulmonary
injury?
Dr. Bando. Thank you very much, Dr. Ungerleider.
Your first question is related to why we use conven-
tional ultrafiltration in the controls. I totally agree with
you that conventional ultrafiltration is not effective
enough because a mean of 20 ml/kg of fluid was filtered
during conventional ultrafiltration, which is about half of
the amount of fluid filtered by dilutional ultrafiltration.
However, dilutional and modified ultrafiltration are rela-
tively new, and for those surgeons who do not use
modified ultrafiltration or dilutional ultrafiltration, con-
ventional ultrafiltration is the standard technique. Thus
we believe it is appropriate to use the conventional
ultrafiltration group as conventional treatment control
patients. Unlike other institutions, we use venovenous
ultrafiltration instead of arteriovenous ultrafiltration. By
use of this technique, it is easy to maintain the desired
filling pressure, and we were able to avoid the significant
arteriovenous shunts during modified ultrafiltration. So
the fear of creating patient hemodynamic instability has
been eliminated.
Regarding the effect of dilutional versus modified ultra-
filtration, that is a valid question. Because the total
amount of endothelin-1 in the dilutional ultrafiltrate is so
small, we may be able to delete the dilutional ultrafiltra-
tion part. However, a possibility also exists that other
mediators that may act as a stimulator for endothelin-1
production are filtered out using dilutional ultrafiltration.
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Thus, as you mentioned, it is important to compare these
two different techniques.
In terms of the significance of plasma endothelin-1, you
are absolutely right. As your laboratory recently demon-
strated in the total circulatory arrest model, it is important
to measure the ET-1 mRNA or ET-1 receptors in the
lung. However, this is only practical in an animal experi-
ment, and we were not able to do that in a clinical
randomized study like this. I would like to mention,
however, that previous studies, including ours, one from
Tokyo Women’s Medical College, and one from Great
Ormond Street Hospital in London, clearly demonstrated
that a significant correlation exists between the plasma
ET-1 level and pulmonary hypertension.
Regarding the question of pulmonary/systemic arte-
rial pressure ratio versus actual pulmonary or systemic
pressure (Appendix 2), we use the Pp/Ps for the follow-
ing reasons: First, this study includes a relatively wide
range of age of the patients from neonates up to 21⁄2
years old; thus the normal arterial pressure may be
different among the patients. Second, as you pointed
out, we did see the increase in systemic pressure after
modified ultrafiltration, about 10 to 15 mm Hg, but this
persisted only an hour or so. Third, we defined preop-
erative pulmonary hypertension as pulmonary/systemic
arterial pressure ratio greater than 60%. For these
reasons, I believe it is still fair to document the Pp/Ps
ratios and compare these parameters between the
groups. Another way to look at this problem is to
express the change of postoperative pulmonary arterial
pressure as the percent change of baseline or preoper-
ative pulmonary arterial pressure. That might help to
answer your question.
You also asked about the timing of injury. The previous
studies show that the ET-1 level was high with patients
with high flow and high pulmonary arterial pressure
preoperatively. Thus pulmonary endothelial function has
been already impaired and CPB merely exaggerates this
injury. So it might be interesting to see the effect of an
ET-1 receptor antagonist administered before CPB versus
after CPB and compare the results.
Regarding the question of bypass technique, except for
one patient in each group with circulatory arrest, we used
the bicaval cannulation and the total CPB. As you men-
tioned, the preoperative Po2 in the control group is
somewhat lower compared with experimental groups, but
this is not statistically significant. I cannot make further
comment on this because the sample size in each group
was relatively small.
Your final question is related to the clinical impression
of which subgroup of the patients might be more vulner-
able to postoperative pulmonary hypertension. I can only
say that you cannot rely on the Pp/Ps ratio immediately
after modified ultrafiltration to predict the degree of
postoperative pulmonary hypertension. We had one pa-
tient with complete atrioventricular canal and Down
syndrome in our preliminary study who had a Pp/Ps of
30% after modified ultrafiltration, and we eliminated the
a-blocker prophylaxis and tried to extubate early. The
patient had a severe pulmonary hypertensive crisis after 3
hours of admission to the intensive care unit and ended up
with extracorporeal membrane oxygenation support for 5
days. We were able to save this patient, but I must say that
this modified ultrafiltration is a valuable adjunct but not a
magic bullet.
Appendix 1. The use of inotropic agents and a-blocker
Control
(n 5 12)
DUF/MUF
(n 5 12)
CP (mg) mean (range) 0.53 (0.25-2) 0.41 (0.25-1.25)
% (No. Pt) 100% (12/12) 100% (12/12)
PR (mg) mean (range) 0.33 (0.125-1.0) 0.15 (0.125)
% (No. Pt) 25% (3/12) 8.3% 9(1/12)
NTG (mg/kg/min) mean (range) 1.5 (0.2-10) 0.8 (0.25-2)
% (No. Pt) 83% (10/12) 50% (6/12)
NIP (mg/kg/min) mean (range) 3.0 (3.0) 0 (0)
% (No. Pt) 8.3% (1/12) (0/12)
Dop (mg/kg/min) mean (range) 4.5 (3.0–10.0) 5.2 (3.0–10)
% (No. Pt) 42% (5/12) 50% (6/12)
Dob (mg/kg/min) mean (range) 4.0 (3.0-7.0) 3.7 (2.5-5.0)
% (No. Pt) 33% (4/12) 25% (3/12)
DUF, Dilutional ultrafiltration; MUF, modified ultrafiltration; CP, chlorpromazine; PR, prazosin, NTG, nitroglycerin; Nip, nitroprusside; Dop, dopamine, Dob,
dobutamine.
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Appendix 3. Preoperative and postoperative arterial blood gas
Preoperative End of operation 3 hr after operation
Control DUF/MUF Control DUF/MUF Control DUF/MUF
pH 7.43 6 0.04 7.44 6 0.10 7.52 6 0.02 7.46 6 0.07 7.44 6 0.07 7.47 6 0.06
PCO2 (mm Hg) 39.0 6 3.0 36.0 6 4.2 27.0 6 4.0 32.4 6 4.5 38.0 6 8.3 32.9 6 3.3
PO2 (mm Hg) 175.0 6 97.5 341.0 6 163.0 282.0 6 66.5 430.0 6 91.0* 184.7 6 49.3 168.9 6 81.7
SaO2 (%) 98.0 6 2.0 98.6 6 2.8 99.5 6 0.5 100.0 6 0 98.0 6 2.9 95.9 6 8.5
FiO2 (%); mean (range) 75 (21-100) 74 (21-100) 100 (100) 100 (100) 80 (50-100) 44 (35-60)
Appendix 4. Requirement of RBC, platelets, FFP
Control
(ml/kg)
DUF/MUF
(ml/kg) p Value
RBC 83.02 6 30.89 67.60 6 24.77 0.42
Platelet 15.29 6 5.95 6.78 6 3.18 0.04
FFP 14.39 6 5.63 6.36 6 3.16 0.04
DUF, Dilutional ultrafiltration; MUF, modified ultrafiltration; RBC, red
blood cell; FFP, fresh frozen plasma.
6 hr after operation 12 hr after operation
Control DUF/MUF Control DUF/MUF
7.46 6 0 7.46 6 0.05 7.51 6 0.07 7.45 6 0.08
34.4 6 8.6 35.1 6 6.3 29.0 6 5.1 33.6 6 5.1
122.7 6 33.0 134.2 6 65 212.6 6 62.3 198.3 6 71.6
98.3 6 1.2 95.9 6 2.3 99.5 6 0.5 100.0 6 0
68 (40-100) 41 (25-50) 66 (40-100) 46 (36-60)
DUF, Dilutional ultrafiltration; MUF, modified ultrafiltration.
*p , 0.005 vs control.
Appendix 2. Changes in actual pulmonary arterial pressure and systemic pressure before, during, and after
surgery
Preoperative Off-bypass End of MUF End of surgery
3 hr
Postoperative
6 hr
Postoperative
12 hr
Postoperative
Pp Control 53.3 6 15.3 36.0 6 13.4 — 41.5 6 5.7 43.5 6 9.9 40.2 6 7.7 36.5 6 7.4
(mm Hg)
DUF/MUF 46.9 6 10.8 29.4 6 11.5 28.9 6 8.1 31.8 6 8.7 32.4 6 9.8 31.9 6 9.3 30.5 6 6.5
(mm Hg)
Ps Control 81.7 6 26.2 73.2 6 16.8 — 74.2 6 13.2 81.5 6 14.0 76.8 6 10.4 77.3 6 14.2
(mm Hg)
DUF/MUF 72.7 6 14.9 69.8 6 17.6 83.9 6 11.5 84.3 6 16.2 83.6 6 11.3 83.9 6 14.6 83.5 6 14.9
(mm Hg)
Pp, Systolic pulmonary pressure; Ps, systemic pressure; DUF, dilutional ultrafiltration; MUF, modified ultrafiltration.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 115, Number 3
Bando et al. 5 2 7
